




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Interventions and ACS</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=9445effd-ba3f-4faa-8061-b82d69552947</link>
        <description>Clinical Topic Feed: Interventions and ACS</description>
        <language>en</language>

        

                <item>
                    <title>EPIC17-VERONICA: Can Platelet Function Testing Guide P2Y12i Deescalation?</title>
<link>/Latest-in-Cardiology/Articles/2026/11/02/22/45/tues-203pm-epic17-tct-2026</link>                    <description>In patients deemed to have very low platelet reactivity, switching from more potent P2Y12 inhibitors to clopidogrel did not improve outcomes at one year, according to findings from the EPIC17-VERONICA trial presented at TCT 2026.</description>
                    <pubdate>1793744100000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PIONEER IV: Angiography-Derived FFR vs. Usual Care in Patients Undergoing PCI</title>
<link>/Latest-in-Cardiology/Articles/2026/11/02/22/45/tues-145pm-pioneer-tct-2026</link>                    <description>Noninferiority of angiography-derived fractional flow reserve (angio-FFR) was not met when compared to usual care in patients undergoing PCI, according to results of the PIONEER IV trial, presented at TCT 2026.</description>
                    <pubdate>1793733600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Interventional Post-ACS Antithrombotic Trials at ESC Congress 2026</title>
<link>/Latest-in-Cardiology/Articles/2026/10/16/17/49/Trials-at-ESC</link>                    <description>Four late-breaking trials, presented at ESC Congress 2026 focused on post-acute coronary syndrome (ACS) antithrombotic therapy.</description>
                    <pubdate>1792177140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Interventional Highlights From LIBREXIA ACS, PREMIUM, SWITCH SWEDEHEART, A-CLOSE, EPIDAURUS</title>
<link>/Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-6am-combo-interventional-esc-2026</link>                    <description>Interventional science was the focus of a Hot Line Session at ESC Congress 2026, with studies shedding light on milvexian with antiplatelet therapy following an acute coronary event; aspirin omission at the time of primary PCI in STEMI; switching from ticagrelor to prasugrel following PCI in patients with acute coronary syndrome (ACS); clopidogrel vs. extended DAPT after high-risk PCI; and potent antiplatelet therapy in patients with atrial fibrillation (AFib) following myocardial infarction (MI).</description>
                    <pubdate>1788005340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Fifth Universal Definition of Myocardial Infarction (2026)</title>
<link>https://www.jacc.org/doi/10.1016/j.jacc.2026.07.025</link>                    <description></description>
                    <pubdate>1787913000000</pubdate>
                    <category>Guidelines</category>
                </item>
                <item>
                    <title>Online Exclusive | SCAI 2026 Roundup: Major Coronary, Structural and Vascular Trials From Montr&#195;&#169;al</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/Online-Exclusive-SCAI-2026-Roundup</link>                    <description>The 2026 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions and CAIC-ACCI Summit, held in Montr&#195;&#169;al, Canada, highlighted the continuing evolution of interventional cardiology through the presentation of several important late-breaking clinical trials.</description>
                    <pubdate>1782908100000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC in a Flash | Consistent Renal Benefit With Semaglutide in T2D/CKD; Late Pericardial Effusion Post LAAO</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1782907800000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>HOST-EXAM: Clopidogrel vs. Aspirin Monotherapy at 10 Years Post PCI</title>
<link>/Latest-in-Cardiology/Articles/2026/04/07/19/53/host-exam-acc-2026</link>                    <description>Clopidogrel monotherapy after PCI was associated with a significantly lower composite risk of all-cause death, nonfatal MI, stroke, readmission for acute coronary syndrome (ACS) and major bleeding compared with aspirin monotherapy, according to 10-year follow-up results of the HOST-EXAM trial presented as featured clinical research at ACC.26 and published simultaneously in The Lancet.</description>
                    <pubdate>1775593440000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>FAST III: Novel Minimally Invasive vFFR Noninferior to FFR For Revascularization</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-830am-fastIII-acc-2026</link>                    <description>Vessel fractional flow reserve (vFFR)-guided revascularization was noninferior to pressure-wire-based fractional flow reserve (FFR)-guided revascularization in patients with intermediate coronary lesions, according to results from the FAST III trial presented during a Late-Breaking Clinical Trials session...</description>
                    <pubdate>1774791180000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: New ACC/AHA Dyslipidemia Guidelines Released</title>
<link>/Latest-in-Cardiology/Articles/2026/03/18/00/50/eagles-eye-view-18mar2025</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life.</description>
                    <pubdate>1773842400000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>